Phase II trial of aclarubicin in epidermoid carcinoma of the head and neck.
D015250:Aclarubicin; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use; D012107:Research Design
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin